Neuronox is a botulinum toxin type A product, used for aesthetic and therapeutic treatments such as glabellar frown lines, essential blepharospasm, and equinus deformity in cerebral palsy. Manufactured by S.Thepharm Co., Ltd., Neuronox offers proven efficacy and safety, demonstrating comparable results to Botox (Allergan Inc.). This lyophilized powder for injection is designed for medical professionals seeking effective muscle relaxant treatments with minimal side effects.
Features:
- Comparable efficacy and safety to Botox (Allergan Inc.)
- Clinical trials show no significant difference in adverse events between Neuronox and Botox
- Contains Clostridium botulinum toxin type A with stabilizers and isotonic agents
- Suitable for various medical conditions such as frown lines, blepharospasm, and muscle spasticity
- Minimal side effects and high safety profile
- Provides reliable results for up to 4-6 months
Applications:
- Glabellar Frown Lines: Temporarily improves moderate to severe glabellar wrinkles related to eyebrow wrinkle muscles (corrugator and/or procerus muscles) in adults aged 20 to 65.
- Essential Blepharospasm: Treatment for benign essential blepharospasm in patients aged 18 and older.
- Equinus Deformity in Cerebral Palsy: Treats equinus foot deformity in pediatric cerebral palsy patients aged 2 years and older.
- Upper Limb Local Muscle Spasticity: For stroke patients with upper limb spasticity aged 20 and above.
Specifications:
- Active Ingredient: Clostridium botulinum toxin type A 100 units (U)
- Stabilizer: Human serum albumin 0.5 mg
- Isotonic Agent: Sodium chloride (EP) 0.9 mg
- Storage: Unopened vials should be stored in a freezer (-5°C) or refrigerator (2–8°C).
- How Supplied: Neuronox is supplied in a single-use vial containing 100 units.
- Expiration: Shelf life of 36 months from the manufacturing date.
Additional Information
- One unit (U) of Neuronox corresponds to the calculated median intraperitoneal lethal dose (LD50) in mice.
- Neuronox has been clinically proven to be non-inferior to Botox in studies for treating glabellar frown lines, blepharospasm, and equinus deformity in cerebral palsy.
- No significant differences were observed in the frequency of adverse events between Neuronox and Botox in clinical trials.
- The product is temperature-sensitive and shipped with ice packs to maintain optimal conditions.